Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation

Human Brain Mapping

Volumn 37, Issue 5, 2016, Pages 1941-1952

  Scheidegger, Milan ^a,b   Henning, Anke ^b,c,f   Walter, Martin ^d   Lehmann, Mick ^a   Kraehenmann, Rainer ^a   Boeker, Heinz ^a   Seifritz, Erich ^a,f   Grimm, Simone ^a,e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c MAX PLANCK INSTITUTE FOR BIOLOGICAL CYBERNETICS   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antidepressants; Depression; Emotional processing; FMRI; Glutamate; Ketamine

Indexed keywords

KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT; OXYGEN;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; CONSCIOUSNESS; CONTINUOUS INFUSION; ELECTROENCEPHALOGRAM; EMOTION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RESTING STATE NETWORK; STIMULATION; AMYGDALA; ANALYSIS OF VARIANCE; BLOOD; DIAGNOSTIC IMAGING; DRUG EFFECT; IMAGE PROCESSING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; PSYCHOMETRY; REACTION TIME; YOUNG ADULT;

ADULT; AMYGDALA; ANALYSIS OF VARIANCE; EMOTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HEALTHY VOLUNTEERS; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KETAMINE; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; PSYCHOMETRICS; REACTION TIME; YOUNG ADULT;

EID: 84963552968     PISSN: 10659471     EISSN: 10970193     Source Type: Journal    
DOI: 10.1002/hbm.23148     Document Type: Article

References (67)

1. Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ (2010): Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139-145.
2. Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ (2012): Ketamine for depression: Where do we go from here? Biol Psychiatry 72:537-547.
3. Abel KM, Allin MPG, Kucharska-Pietura K, Andrew C, Williams S, David AS, Phillips ML (2003a): Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state. Hum Brain Mapp 18:135-145.
4. Abel KM, Allin MPG, Kucharska-Pietura K, David A, Andrew C, Williams S, Brammer MJ, Phillips ML (2003b): Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 14:387-391.
5. Aldhafeeri FM, Mackenzie I, Kay T, Alghamdi J, Sluming V (2012): Regional brain responses to pleasant and unpleasant IAPS pictures: different networks. Neurosci Lett 512:94-98.
6. Anand A, Li Y, Wang Y, Gardner K, Lowe MJ (2007): Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. J Neuropsychiatry Clin Neurosci 19:274-282.
7. Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, Mathews VP, Kalnin A, Lowe MJ (2005): Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. BPS 57:1079-1088.
8. Beck AT (2008): The evolution of the cognitive model of depression and its neurobiological correlates. Am J Psychiatry 165:969-977.
9. Brett M, Anton J, Valabregue R, Poline J (2002): Region of interest analysis using an SPM toolbox. Presented at the 8th International Conferance on Functional Mapping of the Human Brain, June 2-6, 2002, Sendai, Japan: Available on CD-ROM in NeuroImage, Vol. 16, No. 2, abstract 497.
10. Chao-Gan Y, Yu-Feng Z (2010): DPARSF: A MATLAB Toolbox for "Pipeline" Data Analysis of Resting-State fMRI. Front Syst Neurosci 4:13.
11. Chen C-H, Ridler K, Suckling J, Williams S, Fu CHY, Merlo-Pich E, Bullmore E (2007): Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry 62:407-414.
12. Chen C-H, Suckling J, Ooi C, Fu CHY, Williams SCR, Walsh ND, Mitterschiffthaler MT, Pich EM, Bullmore E (2008): Functional coupling of the amygdala in depressed patients treated with antidepressant medication. Neuropsychopharmacology 33:1909-1918.
13. Cullen KR, Klimes-Dougan B, Muetzel R, Mueller BA, Camchong J, Houri A, Kurma S, Lim KO (2010): Altered white matter microstructure in adolescents with major depression: a preliminary study. Ed. Ben J Harrison. J Am Acad Child Adolesc Psychiatry 49:173-183.e1.
14. De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C, Stephenson S, Williams SCR, Mehta MA (2013): Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. NeuroImage 64:75-90.
15. Delaveau P, Jabourian M, Lemogne C, Guionnet S, Bergouignan L, Fossati P (2011): Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. J Affect Disord 130:66-74.
16. Devinsky O, Morrell MJ, Vogt BA (1995): Contributions of anterior cingulate cortex to behaviour. Brain 118:279-306.
17. Dittrich A (1998): The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31 Suppl 2:80-84.
18. Drevets WC (2000): Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 126:413-431.
19. Drevets WC (2003): Neuroimaging abnormalities in the amygdala in mood disorders. Ann N Y Acad Sci 985:420-444.
20. Duman RS, Aghajanian GK (2012): Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68-72.
21. Elliott R, Zahn R, Deakin JFW, Anderson IM (2011): Affective cognition and its disruption in mood disorders. Neuropsychopharmacology 36:153-182.
22. Fu CHY, Williams SCR, Cleare AJ, Brammer MJ, Walsh ND, Kim J, Andrew CM, Pich EM, Williams PM, Reed LJ, Mitterschiffthaler MT, Suckling J, Bullmore ET (2004): Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 61:877-889.
23. Grimm O, Gass N, Weber-Fahr W, Sartorius A, Schenker E, Spedding M, Risterucci C, Schweiger JI, Böhringer A, Zang Z, Tost H, Schwarz AJ, Meyer-Lindenberg A (2015): Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats. Psychopharmacology 232:4231-4241.
24. Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH (2012): Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data. Am J Psychiatry 169:693-703.
25. Hamilton JP, Gotlib IH (2008): Neural substrates of increased memory sensitivity for negative stimuli in major depression. Biol Psychiatry 63:1155-1162.
26. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM (2006): Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. BPS 59:816-820.
27. Henry ME, Lauriat TL, Lowen SB, Churchill JH, Hodgkinson CA, Goldman D, Renshaw PF (2013): Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype. Psychiatry Res 213:217-224.
28. Herry C, Bach DR, Esposito F, Di Salle F, Perrig WJ, Scheffler K, Lüthi A, Seifritz E (2007): Processing of temporal unpredictability in human and animal amygdala. J Neurosci 27:5958-5966.
29. Holtzheimer PE, Mayberg HS (2011): Stuck in a rut: rethinking depression and its treatment. Trends Neurosci 34:1-9.
30. Iannetti GD, Wise RG (2007): BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn Reson Imaging 25:978-988.
31. Josephs O, Henson RN (1999): Event-related functional magnetic resonance imaging: modelling, inference and optimization. Philos Trans R Soc Lond B Biol Sci 354:1215-1228.
32. Khalili-Mahani N, Niesters M, van Osch MJ, Oitzl M, Veer I, de Rooij M, van Gerven J, van Buchem MA, Beckmann CF, Rombouts SARB Dahan A (2015): Ketamine interactions with biomarkers of stress: a randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men. NeuroImage 108:396-409.
33. Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX (2012): Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry 72:898-906.
34. Kong L, Chen K, Tang Y, Wu F, Driesen N, Womer F, Fan G, Ren L, Jiang W, Cao Y, Blumberg H, Xu K, Wang F (2013): Functional connectivity between the amygdala and prefrontal cortex in medication-naive individuals with major depressive disorder. J Psychiatry Neurosci 38:417-422.
35. Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX (2014): Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry 78:572-581.
36. Kringelbach ML, Rolls ET (2004): The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. Prog Neurobiol 72:341-372.
37. Lang P, Bradley M, Cuthbert BN (2008): International affective picture System (IAPS): Affective ratings of pictures and instruction manual. Technical Report A-8. University of Florida, Gainesville, FL.
38. Långsjö JW, Salmi E, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, Viljanen T, Kurki T, Silvanto M, Scheinin H (2004): Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 100:1065-1071.
39. Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA (2009): Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123:143-150.
40. Margulies DS, Kelly AMC, Uddin LQ, Biswal BB, Castellanos FX, Milham MP (2007): Mapping the functional connectivity of anterior cingulate cortex. NeuroImage 37:579-588.
41. Mayberg HS (1997): Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 9:471-481.
42. McCabe C, Mishor Z (2011): Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. NeuroImage 57:1317-1323.
43. Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, Wong E, Tang CY, Charney DS, Iosifescu DV (2015): Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl Psychiatry 5:e509
44. Murrough JW, Iosifescu DV, Chang LC, Jurdi Al RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013): Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134-1142.
45. Outhred T, Das P, Felmingham KL, Bryant RA, Nathan PJ, Malhi GS, Kemp AH (2014): Impact of acute administration of escitalopram on the processing of emotional and neutral images: a randomized crossover fMRI study of healthy women. J Psychiatry Neurosci 39:267-275.
46. Pessoa L, Adolphs R (2010): Emotion processing and the amygdala: from a 'low road' to "many roads" of evaluating biological significance. Nat Rev Neurosci 11:773-783.
47. Phillips ML, Drevets WC, Rauch SL, Lane R (2003): Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry 54:515-528.
48. Pizzagalli DA (2011): Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 36:183-206.
49. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA, Manji HK (2009): Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 65:289-295.
50. Salvadore G, Cornwell BR, Sambataro F, Latov D, Colon-Rosario V, Carver F, Holroyd T, Diazgranados N, Machado-Vieira R, Grillon C, Drevets WC, Zarate CA (2010): Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35:1415-1422.
51. Sarter M, Givens B, Bruno JP (2001): The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brain Res Brain Res Rev 35:146-160.
52. Scheidegger M, Walter M, Lehmann M, Metzger C, Grimm S, Boeker H, Boesiger P, Henning A, Seifritz E (2012): Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS ONE 7:e44799-e44799.
53. Schmidt CF, Degonda N, Luechinger R, Henke K, Boesiger P (2005): Sensitivity-encoded (SENSE) echo planar fMRI at 3T in the medial temporal lobe. NeuroImage 25:625-641.
54. Schmitz TW, Johnson SC (2006): Self-appraisal decisions evoke dissociated dorsal-ventral aMPFC networks. NeuroImage 30:1050-1058.
55. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA (2001): Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. BPS 50:651-658.
56. Sinner B, Graf BM (2008): Ketamine. Handb Exp Pharmacol 313-333.
57. Sladky R, Spies M, Hoffmann A, Kranz G, Hummer A, Gryglewski G, Lanzenberger R, Windischberger C, Kasper S (2015): (S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling. NeuroImage 108:243-250.
58. Song X-W, Dong Z-Y, Long X-Y, Li S-F, Zuo X-N, Zhu C-Z, He Y, Yan C-G, Zang Y-F (2011): REST: a toolkit for resting-state functional magnetic resonance imaging data processing. PLoS ONE 6:e25031.
59. Spielberger CD, Gorsuch RL, Edward LR (1970): STAI manual for the state-trait anxiety inventory ("Self-evaluation questionnaire"). Consulting Psychologists Press, Inc.
60. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M (2002): Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 15:273-289.
61. van Marle HJF, Tendolkar I, Urner M, Verkes RJ, Fernández G, van Wingen G (2011): Subchronic duloxetine administration alters the extended amygdala circuitry in healthy individuals. NeuroImage 55:825-831.
62. Victor TA, Furey ML, Fromm SJ, Ohman A, Drevets WC (2010): Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry 67:1128-1138.
63. Vollenweider FX, Kometer M (2010): The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642-651.
64. Walter M, Li S, Demenescu LR (2014): Multistage drug effects of ketamine in the treatment of major depression. Eur Arch Psychiatry Clin Neurosci 264(Suppl 1):55-65.
65. Yoshimura S, Okamoto Y, Onoda K, Matsunaga M, Ueda K Suzuki S-I, Shigetoyamawaki (2010): Rostral anterior cingulate cortex activity mediates the relationship between the depressive symptoms and the medial prefrontal cortex activity. J Affect Disord 122:76-85.
66. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006): A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
67. Zhong M, Wang X, Xiao J, Yi J, Zhu X, Liao J, Wang W, Yao S (2011): Amygdala hyperactivation and prefrontal hypoactivation in subjects with cognitive vulnerability to depression. Biol Psychol 88:233-242.